Medicus Economics, LLC on LinkedIn: Real-world treatment patterns and overall survival among men with…
Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis–Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting - European Urology ...
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Overall survival and second primary malignancies in men with metastatic prostate cancer | PLOS ONE
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
mCRPC: PREVAIL Trial | HCP Site | XTANDI® (enzalutamide)
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
Frontiers | Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel
Progression-free survival of mCRPC patients treated with AAP | Download Scientific Diagram
Efficacy I PLUVICTO
Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study | BMC Cancer | Full Text
Full article: A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
Latest developments in prostate cancer treatment
A Retrospective Study of the Effect of Metformin on Patients with Metastatic Prostate Cancer - Chung-Shien Lee, So Yi Lam, Angel Liu, Cristina Sison, Xin-Hua Zhu, 2023
ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone
PROpel Trial Efficacy – LYNPARZA® (olaparib) for BRCAm mCRPC
Overall survival. mCRPC metastatic castration-resistant protate cancer.... | Download Scientific Diagram
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design -
Overall Survival (OS) for mCRPC patients treated with docetaxel for a... | Download Scientific Diagram
Pharmaceutics | Free Full-Text | Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using 177Lu-iPSMA and 177Lu-DOTATOC: Experience after 905 Treatment Doses
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study - ScienceDirect
First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC - Medical Conferences
